With approvals for botulinum toxin injectables in over 70 countries worldwide, Hugel has demonstrated its R&D capabilities that meet global standards.
The venture companies we supported have attracted a total of 38 billion won in follow-up investments, been selected for national R&D projects, and named to the SLUSH 100, Europe's largest startup conference.
By the Ministry of Science and ICT, Hugel has been selected as a "Certified Outstanding R&D Center," proving its technological innovation capabilities and value creation.
Hugel's botulinum toxin is proven for its consistent and stable potency, ensuring its effectiveness and safety through global and domestic clinical trials. We aim to maximize the therapeutic effects of botulinum toxin through expanding its indications and improving its formulations.
To maximize the effectiveness of hyaluronic acid fillers, we are developing fillers with various functionalities, aiming to offer a wide range of fillers tailored to customers' needs.
By providing patients with non-surgical treatment opportunities for fat reduction, we are focusing on building a new portfolio in medical aesthetics.
We are developing a new product line of absorbable thread composed of biocompatible proteins, which offer more than twice the longevity compared to PDO components, along with high elasticity, flexibility, and softness.
